.svg)
BLOG
The Latest on Solid IO
Solid IO welcomes new international investors
Leo Capital and Life Science Invest have joined Solid IO to support the company's next phase of growth in personalized immuno-oncology.
Lung Cancer Awareness Month – Confronting the World’s Deadliest Cancer
November marks the international Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer-related deaths worldwide, with more than two million new cases diagnosed each year.
Solid IO Awarded European Partnership for Personalized Medicine Grant
This competitive EU funding instrument accelerates Solid IO’s progress and strengthens it's position in the personalized medicine space.
Solid IO Awarded €400 000 R&D Grant From Business Finland
This significant early-stage public funding strengthens our position as a developer of next-generation precision oncology diagnostics and enables us to accelerate our path toward market entry.
Strategic Funding: More than just capital
Solid IO closed its first equity funding round immediately after spinning out from the University of Helsinki.
Solid IO Raises € 800 000 to Eliminate the Guesswork in Cancer Care
The Funding will Support Next-Generation Tumor Modeling for Precision Oncology & Immunotherapy Advancements
Shape the future of cancer care
Join SolidIO in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.